Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1. fázis

A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

A legfontosabb adatok

Ki végzi
Icahn School of Medicine at Mount Sinai
Hol
New York (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
1. fázis
Résztvevők
20 fő vett részt
Kezdés
2025. aug. 12.
Várható befejezés
2027. jún. 15.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • lamivudine
  • rapamycin
  • Exercise Regimen
  • Spermidine
A regiszteradat frissítve
2026. augusztus 27.

Ki vehet részt

Életkor
60 év – 85 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients 60-85 years old
  • Current or former smokers
  • BMI 25-35
  • No cancer requiring active therapy within the last 2 years
  • No autoimmune disease requiring disease modifying agents
  • No patients with EGFR <30 or ESRD
  • No class 3 or 4 heart failure

Ki nem vehet részt

  • Patients may not be receiving immune modifying biologic therapies
  • Patients may not have clinically significant active wound healing due to recent injury or surgery
  • Patients may not have received a live virus within one month of study initiation
  • Patients may not be receiving any chronic immunosuppressive therapy
  • Patients may not be receiving medications that could increase rapamycin blood concentrations, such as strong inhibitors and inducers of CYP3A4 and/or P-gp (ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin; rifampin or rifabutin), bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, protease inhibitors, metoclopramide, nicardipine, troleandomycin, verapamil. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort
  • Patients may not be receiving medications that could decrease rapamycin blood concentrations, such as: carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort
  • Patients may not be receiving medications known to cause angioedema with concomitant use of rapamycin, such as angiotensin-converting enzyme (ACE) inhibitors. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort
  • Patients may not have cancer requiring active therapy within the last 2 years
  • Patients may not have autoimmune disease requiring disease modifying agents
  • Patients may not have chronic kidney disease stage 3/4 or end stage renal disease
  • Patients may not have a known history of metabolic dysfunction-associated steatohepatitis
  • Patients may not have a known chronic viral infection such as HIV or active Hepatitis B or C, or a known history of genital HSV. Patients who have spontaneously or through treatment cleared hepatitis B or C are candidates for the trial. If Hepatitis B core ab is positive must document a negative PCR
  • Patients may not have class 3 or 4 heart failure, or have experienced a myocardial infarction or cerebrovascular event in the past 6 months
  • Patients may not have uncontrolled diabetes mellitus
  • Patients may not have a history of clinically significant interstitial lung disease (ILD)
  • Patients may not have evidence of active or latent tuberculosis
  • Patients cannot have uncontrolled hypertension (persistent systolic >160; diastolic >100)
  • Patients may not have a history of, or current evidence of, clinically significant chronic liver disease
  • Patients may not have signs or symptoms of clinically significant acute infectious illness on screening laboratory testing or physical examination
  • Patients may not have nephrotic range proteinuria on screening labs
  • Patients with an inherited primary immunodeficiency

Helyszínek itt: Egyesült Államok

  • Mount Sinai HospitalNew York, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.

A vizsgálat 2 csoportja

  • Exercise and spermidine administered in conjunction with lamivudine (RTi)A vizsgált kezelés

    Participants will perform an exercise regimen and take spermidine and lamivudine for 180 days.

    Kezelés: lamivudine, Exercise Regimen és Spermidine

  • Exercise and spermidine administered in conjunction with rapamycin (mTORi)A vizsgált kezelés

    Participants will perform an exercise regimen and take spermidine and rapamycin for 180 days.

    Kezelés: rapamycin, Exercise Regimen és Spermidine

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 1b, Multi-cohort Clinical Trial Assessing Safety and Feasibility of Exercise and Spermidine Administered in Conjunction With Lamivudine (RTi) or Rapamycin (mTORi) to Assess Impact on Dynamic Changes of Inflammation and Aging
A regiszteradat frissítve
2026. augusztus 27.